Core Viewpoint - Federal Pharmaceutical (03933) has made significant advancements in the GLP-1 treatment area, showcasing its new diabetes management products and forming strategic partnerships to enhance its global market presence [1] Group 1: Stock Performance - Federal Pharmaceutical's stock rose over 4%, reaching HKD 59.95 with a trading volume of HKD 31.28 million [1] Group 2: Product Development - The company highlighted its diabetes management product lineup at the conference, including the recently launched liraglutide injection "Federal Yuli Tai" and the upcoming semaglutide injection "Federal Youmei Tai," expected to launch next year [1] - The introduction of these products marks a significant milestone for Federal Pharmaceutical in the GLP-1 target treatment field [1] Group 3: Strategic Partnerships - Federal Pharmaceutical's subsidiary, Federal Bio, has entered into an exclusive licensing agreement with Novo Nordisk for UBT251, which underscores the global market potential of UBT251 [1] - This collaboration is expected to leverage Novo Nordisk's resources to accelerate the global development of UBT251 [1] - The partnership represents a key achievement in Federal Pharmaceutical's innovation transformation, aligning its GLP-1 innovative drugs with international standards and enhancing the international influence of domestic GLP-1 medications across nearly 80 countries and regions [1]
联邦制药午前涨超4% 公司降糖新品备受关注 司美格鲁肽注射液预计明年上市